ArcDia has entered into an exclusive license agreement with Xinhua Healthcare

  • Turku-based ArcDia International brings its medical devices to the Chinese market
  • This deal gives ArcDia a significant scale advantage
  • ArcDia focuses on the development of innovative products for the decentralized testing of infectious diseases

ArcDia International Oy Ltd, manufacturer of the successful mariPOC® infectious diseases testing platform, has entered into an exclusive license agreement with Xinhua Healthcare Industry Co Ltd, a subsidiary of one of the largest medical device conglomerates in China.

The parties aim to localize ArcDia’s mariPOC® testing platform in China, and to build-up production capacity to respond the increasing demand for decentralized infection diagnostic services in China. Under the terms of the license agreement, ArcDia will supply Xinhua Healthcare with critical biochemical assay components and to provide Xinhua Healthcare with R&D services. The license is limited to the P.R. China.

Televisiokamera ja kameramies kuvaamassa miestä ja naista.
A TV-channel from St.Petersburg got acquainted with ArcDia’s maripoc-technology in 2017.

We are very excited about this deal and partnership with Xinhua Healthcare. ArcDia and Xinhua Healthcare are a perfect match and the agreement presents ArcDia with an opportunity to better serve the growing Chinese market”, says Dr Aleksi Soini, CEO of ArcDia International Ltd. “The Chinese government is investing heavily in health care, and I believe that China could become the leading country in infection management within a few years. Moreover, this deal gives ArcDia a significant scale advantage, which also improves the competitiveness of the mariPOC® platform in western markets”, continues Dr Soini.

“This agreement allows Xinhua Healthcare to expand its IVD business in point-of-care testing (POCT) for infections – the market that is growing at the highest pace in China”, says Mr Li Chuancun, Chairman of Xinhua Healthcare Ltd. “We have found that there is a large market demand for ArcDia’s products and technology in China. The mariPOC® platform allows the implementation of cost-efficient decentralized diagnostics services, which is an element of the strategic focus of our Government’s health care policy”, Mr Li continues.

ArcDia International Oy Ltd is a private company focused on the development of innovative products for the decentralized testing of infectious diseases. The company based in Turku, Finland, was founded in 2008 and employs now 28 skilled professionals. ArcDia is the developer and manufacturer of the mariPOC® IVD platform – an automated system designed for the rapid multianalyte identification of pathogens, and the detection of inflammation markers and antimicrobial resistance. The current mariPOC® application portfolio covers respiratory tract infections, tonsillitis and gastroenteritis. More information about ArcDia, including mariAST® developed for rapid phenotypic antibiotic resistance testing, and mariCloud™ for real-time influenza surveillance, is available at www.arcdia.com.